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Objective: To investigate the frequency of childhood and adult
attention deﬁcit hyperactivity disorder (ADHD) symptoms in a cohort
of patients with schizophrenia (SCZ).
Methods: A systematic review was conducted to evaluate existing
evidence. Two self-report questionnaires were used to investigate adult
ADHD and childhood ADHD symptoms in 126 patients with ICD-10
diagnoses of SCZ.
Results: Five studies were included in the systematic review, with the
prevalence of childhood and adult ADHD in SCZ subjects ranging
between 17–57% and 10–47% respectively. Within our cohort, 47% of
patients reported positive screening for ADHD symptoms either in
childhood or adulthood. 23% reported symptomatology consistent with
both childhood and adult ADHD.
Conclusions: We demonstrate a greater presence of ADHD
symptomatology in SCZ compared to that reported for ADHD in the
general population. Our ﬁndings highlight the importance of improved
clinical assessment and treatment considerations in a subgroup of
patients with SCZ.
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Signiﬁcant outcomes
• 23% of patients with schizophrenia report childhood and adult attention deﬁcit hyperactivity disor-
der symptoms compared to 2.5% of adults diagnosed in the general population.
Limitations
• The questionnaires are not diagnostic.
• Patients in the sample were not screened for active SCZ or mood symptoms.
• The lack of a new control group from the general population for comparison purposes.
Introduction
Schizophrenia (SCZ) and attention deﬁcit hyperac-
tivity disorder (ADHD) are both neurodevelopmen-
tal disorders. SCZ is deﬁned by the presence of
psychotic symptoms, disorganised speech/behaviour
and negative symptoms, such as avolition and alogia
(1). However, neurocognitive deﬁcits are increas-
ingly recognised as a core feature of SCZ, associated
with functional outcomes (2) and quality of life (3,
4). SCZ has a population prevalence of approxi-
mately 1% (5), with a male-to-female ratio of 1.4 : 1
(6). ADHD is a behavioural disorder characterised
by pervasive and impairing symptoms of inatten-
tion, hyperactivity and impulsivity before the age of
12 (7). The prevalence in children aged 18 or
younger is estimated to be 5.29% (8), with a male-
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to-female ratio of 4 : 1 in the general population (9).
Diagnostic follow-up studies have conﬁrmed
ADHD can persist into adulthood with an estimated
prevalence of 2.5% in the adult population (10).
Furthermore, the symptoms of ADHD in childhood
and their persistence into adulthood have been
reported to be 10.1% and 4.6%, respectively, in a
general adult population (11).
The presentation of SCZ can include varying
degrees of attentional dysfunction (12, 13), a cen-
tral cognitive deﬁcit observed in patients with SCZ
(2). Recent work has revealed a genetic correlation
between SCZ and ADHD, meaning that there is
some overlap between the risk alleles for SCZ and
for ADHD (14). Speciﬁcally, the genetic correla-
tion (rg) between the two disorders has been esti-
mated to be 0.122 (P = 0.0007) (15). Prodromal
attention deﬁcit symptoms have retrospectively
been identiﬁed in patients with SCZ (16), and a
prospective study in a Danish cohort has shown
that a diagnosis of ADHD is a strong risk factor
(RR 4.3) for the development of SCZ (17). Addi-
tionally, an odds ratio of 6.7 (95% CI 5.9–7.5) for
probands with ADHD to develop SCZ was
reported in a Swedish cohort (18). Furthermore,
the most common comorbid condition found in
childhood-onset SCZ is ADHD, at 84% (19).
Thus, ADHD-like features have been suggested to
be an early vulnerability marker for SCZ (20).
Aims of the study
We aimed to:
(i) Systematically review studies that have esti-
mated the prevalence of childhood and adult
ADHD in patients with schizophrenia
(ii) Estimate the prevalence of childhood and
adult attention deﬁcit hyperactivity disorder
symptoms in a cohort of patients diagnosed
with schizophrenia (UCL genetics of
schizophrenia cohort).
Methods
Systematic review of prevalence of ADHD in people with
schizophrenia
We systematically reviewed the literature relating
to the prevalence of childhood ADHD (cADHD)
and the persistence in adulthood of the condition
(c+aADHD) in patients with SCZ using the
PRISMA criteria (21). Eligible studies included
patients with a SCZ spectrum disorder as deﬁned
by DSM-IV or DSM-V or ICD-10 (the 10th
revision of the International Statistical Classiﬁca-
tion of Disease and Related Health Problems) (22).
MEDLINE and PsycINFO were searched via
OvidSP using the terms: ([Attention deﬁcit hyper-
activity disorder] OR [ADHD] AND [Schizophre-
nia] AND [Prevalence]) on, 29 May 2018. A
manual search of the literature was also conducted.
Only studies reported in English were considered
for the review. Study selection was performed by
two reviewers (IA and GG).
The outcome measures were the percentage of
patients with SCZ that had a clinical diagnosis of
ADHD or ADHD symptoms, as determined by
interviews and self-report. A data extraction table
capturing the relevant information was developed.
Data items extracted included: the number of trial
participants, the age range of participants, method
of diagnosis of trial participants, methods for
assessing the occurrence of ADHD symptoms in
trial participants and the outcome measure of
prevalence.
Estimation of prevalence of ADHD symptoms in UCL genetics of
schizophrenia cohort
Participants. The SCZ cohort of the UCL DNA
Polymorphisms in Mental Illness (DPIM) has been
described previously (23). Brieﬂy, participants were
recruited from NHS services. Potential partici-
pants with an ICD-10 diagnosis of schizophrenia
were interviewed using the Schedule for Aﬀective
Disorders and Schizophrenia-Lifetime version
(SADS-L) (24), and the 90-item Operational Crite-
ria Checklist (OPCRIT) was also completed (25).
Participants who achieved a Research Diagnostic
Criteria (RDC) (26) diagnosis of schizophrenia
with the SADS-L were included. Ethical approval
was granted for the study by the NHS National
Research Ethics Service, NRES Committee South
Central – Southampton A (formally the
Metropolitan Multi-centre Research Ethics Com-
mittee) REC Reference Number: 03/11/090. Writ-
ten informed consent was obtained from each
participant. For the SCZ and attention deﬁcit and
hyperactivity symptom study described here, 1000
participants from the SCZ cohort of the UCL
DPIM study were invited to participate by letter.
Assessment of ADHD symptoms. Validated tools
were used for the assessment of cADHD symp-
toms and adult ADHD symptoms (aADHD). The
25-item version of the Wender Utah Rating Scale
(WURS) provided information about symptoma-
tology consistent with cADHD based on DSM cri-
teria (27). The part-A screening test from the
Adult ADHD Self-Report Scale (ASRS) was
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utilised to identify the presence of symptoms con-
sistent with aADHD (28).
OPCRIT and/or SADS-L data were available
for 106 of 126 of the participants with SCZ. The
earliest age when medical advice was sought or the
age of onset of ﬁrst psychiatric condition (AOO),
the age at study entry (ASE), the presence of can-
nabis abuse/dependence, the presence of alcohol
abuse/dependence, the presence of any abuse/de-
pendence (cannabis/alcohol/other), a family his-
tory of SCZ, a family history of other psychiatric
condition and the length of schooling were
extracted from the phenotypic data and used as
covariates.
Statistical analysis
Stata (version 14) was used for all statistical analy-
ses (29). Data cleaning was performed. Responses
were checked for missing or inconsistent data. Par-
ticipants who returned more than three missing
answers on the WURS or more than one on the
ASRS were excluded.
The total scores for the WURS and ASRS were
calculated for each participant. Data imputation
was performed using the subject’s average score for
the questionnaire aﬀected. A suitable cut-oﬀ for
each scale was applied to dichotomise the data for
analysis. As there was no evidence for the best
WURS cut-oﬀ score in patients with SCZ, we used
a cut-oﬀ at 46 of 100 due to its greater discrimina-
tory power in patients with unipolar depression (27).
The ASRS has a maximum score of 30 (six ques-
tions with maximum score of 5). Each question has
a diﬀerent ‘cut-oﬀ’ for what is classiﬁed as a signiﬁ-
cant symptom, so for one question it might be 3/5
and for the other 4/5. If a person achieves the cut-
oﬀ in four of the six questions, they are considered
to have symptoms that are highly consistent with
ADHD in adults, warranting further clinical investi-
gation (28). In order to implement a questionnaire-
wide cut-oﬀ score, each question was coded to either
1 or 0 depending on whether its cut-oﬀ was reached.
Scores of 4 and above were considered positive, and
less than 4 were considered to be negative.
To compare the means of continuous variables,
we utilised either the t-test or the nonparametric
Mann–Whitney U-test following assessment for
normality. A one-way analysis of variance was
used to compare groups of participants with diﬀer-
ent lifetime prevalences of ADHD symptomatol-
ogy for AOO and ASE. Linear regression of these
covariates with WURS and ASRS scores was also
carried out to conﬁrm the association.
The Mann–Whitney U-test was utilised to com-
pare whether scoring of each questionnaire was
aﬀected by diﬀerent covariates. To conﬁrm these
ﬁndings, linear regression was carried out on those
covariates that produced indicative signiﬁcance at
the 5% level.
Results
Systematic review findings
The systematic search identiﬁed 299 studies. After
removal of duplicates, and ﬁltering to English-only
studies, 226 studies remained. Title and abstract
screening identiﬁed 10 studies for detailed review.
Five articles fulﬁlled our inclusion criteria, three
following the above literature search and 2 from a
manual search of databases and reference lists of
articles.
Prevalence estimates for cADHD in patients
aﬀected by SCZ ranged from 17 to 57%. Only two
studies measured the prevalence of ADHD comor-
bidity in adulthood, reporting 10% and 47%,
respectively, see Table 1 (30, 31). Table 2 details
the study characteristics of each eligible study.
Prevalence of lifetime ADHD symptoms in UCL genetics of
schizophrenia cohort
Consent-to-participate forms were received from
194 of the 1000 participants invited to take part.
Questionnaires were received from 131 subjects; 5
(3.8%) had to be excluded due to the level of miss-
ing data leaving a ﬁnal sample size of 126 (83
(65.9%) men and 43 (34.1%) women). Of these
participants, 10 (7.9%) required imputation for
one value, 9 (7.1%) for two values and 3 (2.4%)
for three missing values. Participants included in
the study were aged 21–85.
Twenty-three per cent of participants with SCZ
reported symptoms of ADHD in childhood per-
sisting through to adulthood. Symptoms of
cADHD only were reported by 11.1%, and
aADHD only by 12.7%. The remaining 53.2% of
participants reported no ADHD symptoms. In
Table 1. Prevalence of cADHD and/or aADHD reported in the current literature for
patients with SCZ
Author/Source Reported prevalence Sample (N)
Peralta et al. (2011) (33) 17% cADHD 112
Dalteg et al. (2014) (31) Sample 1 57% cADHD
47% cADHD + aADHD
119
Sample 2 + 3 50% cADHD 247
Rubino et al. (2009) (34) 42.6% cADHD 197
Hallerb€ack et al. (2014) (30) 10% cADHD + aADHD 41
Donev et al. (2011) (32) 44.4% cADHD 27
cADHD, childhood ADHD; aADHD, adulthood ADHD.
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total, 34.1% of 126 subjects with SCZ reported
symptomatology consistent with childhood
ADHD. Table 3 shows the breakdown of each cat-
egory for ADHD symptomatology.
As part of the phenotypic data set collected for
the DPIM study, information on the AOO was
available for 106 participants and ASE for 99. A
one-way analysis of variance revealed no signiﬁ-
cant diﬀerence in the AOO (P = 0.60) or ASE
(P = 0.40) in any of the four ADHD symptom
groups (cADHD, aADHD, c+aADHD and no
ADHD). A linear regression of AOO with ASRS
or WURS scores also showed no signiﬁcance
(P < 0.05).
Secondary analyses
OPCRIT and SADS-L variables were selected to
examine their inﬂuence on mean WURS and
ASRS scores, as shown in Table 4.
Univariate linear regression analyses were car-
ried out for variables with signiﬁcant associations
at the 5% level in Table 4. Regression for the his-
tory of any substance abuse with WURS
(P = 0.0071) and ASRS (P = 0.0015) was signiﬁ-
cant, and a linear regression of ASRS scores on a
history of alcohol abuse showed a signiﬁcant asso-
ciation, F (1, 99) = 8.99, P = 0.0034.
Discussion
A systematic review of the published literature of
ADHD symptomatology in schizophrenia patients
identiﬁed only ﬁve previous studies, with small
sample sizes and heterogeneous study methodolo-
gies. For example, Hallerb€ack et al. and Donev
et al. had a sample size of 41 and 27 patients
respectively (30, 32). There were also diﬀerences
between studies in the criteria used to deﬁne
ADHD. For example, Dalteg et al. (31) deﬁned
ADHD by a ‘typical pattern of problems’ and
Donev et al. (32) adopted a less stringent cut-oﬀ
value for the WURS. The studies also varied in the
ascertainment method of schizophrenia patients.
For example, Peralta et al. (2011) included
patients suﬀering from ﬁrst episode SCZ spectrum
psychosis (33), Rubino et al. (2009) included in-
patients with adult-onset SCZ (34), and Hallerb€ack
et al. (2014) included patients ascertained from an
adult psychiatric clinic (30). The majority of stud-
ies only assessed cADHD symptoms in patients
with SCZ and therefore were susceptible to recall
bias. Only two studies investigated the prevalence
of ADHD comorbidity. The ADHD symptom
prevalence results from our study fall in the mid-
range for prevalence of both c+aADHD and
cADHD reported in the literature for people suf-
fering from SCZ (Table 1).
In our cohort, we found 23% of participants
with SCZ to have symptomatology consistent with
c+aADHD, increasing to 34.1% when including
cADHD only. Despite the heterogeneity in the
studies of ADHD in SCZ, all estimates of ADHD
prevalence and our estimate of symptomatology
indicate that ADHD is more common in SCZ
than in the general population. The general popu-
lation prevalence of ADHD diagnosis has been
estimated to be 5.3% in childhood and 2.5% in
adults (8, 10). This rises to 10.1% for cADHD
and 4.6% for c+aADHD in a general population
sample from Germany (limited to 18- to 64-year-
Table 3. Prevalence of cADHD and/or aADHD symptomatology reported by patients
with SCZ in the UCL genetics of schizophrenia cohort
Lifetime ADHD
symptomatology Freq: (N = 126) Per cent (%) Age range
Gender N (%)
male
c+aADHD 29 23.0 23–77 19 (65.5)
aADHD only 16 12.7 35–70 10 (62.5)
cADHD only 14 11.1 29–65 9 (64.3)
No ADHD 67 53.2 21–85 45 (67.2)
cADHD, childhood ADHD symptomatology; aADHD, adulthood ADHD symptomatol-
ogy; c+aADHD, child and adulthood ADHD symptomatology.
Table 4. Mean WURS and ASRS scores with the presence of covariates in the UCL genetics of schizophrenia cohort
Covariate N
WURS ASRS
Mean score Analyses Mean score Analyses
History of alcohol dependence: Y/N 101 Y: 47.6 (6.8)
N: 34.8 (2.4)
U = 11555.7 P = 0.062 Y: 20.7 (1.6)
N: 16.4 (0.5)
U = 11514.6 P = 0.015*
History of cannabis dependence: Y/N 71 Y: 41.5 (8.0)
N: 37.6 (3.0)
U = 3022.4 P = 0.48 Y: 19.8 (2.4)
N: 17.4 (0.7)
U = 3012.3 P = 0.26
History of any abuse/dependence: Y/N 106 Y: 48.3 (5.5)
N: 32.8 (2.3)
U = 14730.9 P = 0.0048* Y: 20.6 (1.3)
N: 16.5 (0.5)
U = 14673.3 P = 0.0043*
Education-A high school graduate: Y/N 73 Y: 35.5 (2.9)
N: 46.4 (7.6)
U = 5091.2 P = 0.14 Y: 17.5 (0.7)
N: 18.4 (1.8)
U = 5069.0 P = 0.47
WURS, Wender Utah Rating Scale; ASRS, Adult ADHD Self-Report Scale; Y/N Yes/No; *: Significant at 5% level, statistical comparison utilised the Mann–Whitney U-test.
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olds) where the WURS and ASRS were used to
estimate prevalence (11). In our study, 35.7% of
participants reported ADHD symptoms in adult-
hood, and this is higher than reported estimates of
adult ADHD symptomatology in the general pop-
ulation of 5.7–10.9% obtained using the ASRS
(35–37).
Current diagnostic criteria for ADHD require
the onset of symptoms in childhood, that is, before
the age of 12 in DSM-5 and before the age of 7
according to the ICD-10. Interestingly, although
35.7% of participants with SCZ reported aADHD
symptoms, 12.7% did not report symptomatology
suggestive of cADHD. Longitudinal studies of epi-
demiological cohorts in Brazil (38), UK (39) and
New Zealand (40) have recently reported the pres-
ence of adult-onset ADHD in the absence of child-
hood-onset ADHD. This provides support for a
model whereby adult-onset ADHD is not necessar-
ily a continuation of childhood-onset ADHD, sug-
gesting that there may be distinct developmental
trajectories. It remains unclear whether adult-onset
ADHD is a separate diagnostic entity or whether it
is an artefact of misdiagnosis or overlapping crite-
ria (methodological bias). Ideally, a diagnosis in an
adult is a process that should include a retrospec-
tive analysis of the ADHD symptoms in child-
hood. We ﬁnd the same results as the longitudinal
epidemiological ADHD studies, whereby only a
proportion of patients with SCZ meet the criteria
for adult-onset ADHD and this would be an
important group to study in further research.
Despite AOO being conceptualised as a surro-
gate measure of severity (41), and an earlier age of
onset being associated with more severe cognitive
impairments in SCZ (42), our results did not sug-
gest a signiﬁcant association between age of onset
of SCZ and ADHD symptoms. There was also no
evidence that the age at which people entered the
study inﬂuenced their childhood or adult ADHD
scores suggesting that this was not a major factor
that inﬂuenced recall of symptoms. In line with the
literature, higher ADHD scores were predictive of
a history of any abuse/dependence (43) and were
implicated in poorer outcome and treatment com-
pliance in SCZ (44). Also in line with the literature
are the ﬁndings that participants reporting
aADHD symptoms are more vulnerable to alcohol
abuse (45). Thus, diagnosing comorbidities in clini-
cal practice could help to identify those most at
risk of poorer outcomes and improve interventions
and support.
There is currently a lack of recommended phar-
macological treatments for people experiencing
comorbid SCZ and ADHD (46). SCZ is primarily
treated with dopamine D2-antagonists or partial
agonists that are often classed as typical or atypical
antipsychotics. ADHD in contrast is treated with
‘dopamine enhancers’, through blockers of the
presynaptic dopamine transporter (DAT) and/or
noradrenalin transporters (47). Furthermore,
patients with comorbid ADHD fail to respond to
antipsychotics for their SCZ have poorer outcomes
(48) and are vulnerable to the lack of treatment
focus on the cognitive impairments seen in patients
with SCZ (49). Reports have suggested that psy-
chostimulants typically used in ADHD can allevi-
ate the negative symptoms (50) and cognitive
deﬁcits (51) of SCZ; however, there is evidence
showing their potential dangers in triggering psy-
chotic symptoms, leaving room for further debate
(52, 53). None of the participants in our study
reported being prescribed psychostimulants.
This study has multiple limitations which must
be acknowledged. First, the sample size was mod-
est, but is similar to comparable studies in the liter-
ature. More precise estimates of the prevalence of
cADHD and/or aADHD in SCZ will require much
larger sample sizes. Second, the sample comprised
of participants who volunteered to take part in the
DPIM study and responded to the invitation to
take part in the study extension exploring the
prevalence of inattentiveness, hyperactivity or
impulsiveness in people living with schizophrenia.
The response rate was below 20%. Moreover, the
participants had to complete and return two let-
ters. These factors likely biased the cohort towards
people with higher levels of functioning and may
impact the applicability of the study data to other
settings.
Third, the gold standard assessment for ADHD
in adults is the Diagnostic Interview for ADHD in
Adults (DIVA) (54); however, we did not speciﬁ-
cally aim to diagnose ADHD in our cohort but
aimed to assess ADHD symptomology as a mea-
surement of a continuous variable. Furthermore,
we were not able to conduct face-to-face interviews.
Fourth, we did not have a measure of current SCZ
symptomology when ADHD symptoms were
assessed. Additionally, current mood symptoms
were not assessed, which may also have had an
eﬀect on ADHD symptom scores, and the WURS
is vulnerable to recall bias. Another limitation is
that the ASRS has not been validated in patients
with SCZ. This might lead to the risk of methodical
overlap between symptoms that are more relevant
to ADHD with those that are more relevant to SCZ
or to functional cognitive impairment. Moreover,
we opted to include only part A of the ASRS which
has been shown to have a positive predictive value
of up to 94.7 at detecting clinical cases of adult
ADHD (28). Our decision was guided by the aim of
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keeping our questionnaire items to the lowest possi-
ble number, in order to maximise responses. By
doing so, however, we recognise the reduced ability
to perform ADHD subtyping. Future work using
the full 18-item ASRS in participants suﬀering from
SCZ has the potential to reveal interesting and
important insight into subtypes of ADHD that are
observed in SCZ.
We report a higher prevalence of ADHD symp-
toms in patients with SCZ, as compared to the
prevalence of ADHD symptoms within the general
population. These ﬁndings likely reﬂect a degree of
overlapping symptomatology for the two disorders
and also some of the shared genetic aetiology that
has been identiﬁed in recent genomewide associa-
tion studies (15). The importance of these ﬁndings
lies in the contrasting therapies recommended for
each condition.
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